EVIDENCE LIBRARY
Gabapentinoid Study Used Alprazolam or Diazepam as Comparators and Prescriptions as an Atrial-Fibrillation Proxy
A claims study found more initiation of atrial-fibrillation-related treatment after gabapentinoids. It did not directly diagnose every event or demonstrate that benzodiazepines prevent arrhythmia.
A claims study found more initiation of atrial-fibrillation-related treatment after gabapentinoids. It did not directly diagnose every event or demonstrate that benzodiazepines prevent arrhythmia.
The operational outcome
Older adults newly receiving gabapentin or pregabalin were compared with opioid users and with alprazolam or diazepam users. The outcomes were combinations of new antithrombotic and antiarrhythmic prescriptions over three months.
Associations favored the comparator groups, but the study’s event definition was a treatment proxy rather than direct rhythm adjudication.
Comparator and indication limits
Patients receiving different medicines can differ in pain, anxiety, comorbidity, and healthcare contact. Limited clinical information prevented full adjustment for those factors. A prescription combination may also have explanations other than newly confirmed atrial fibrillation.
The result is a safety signal for further study, not proof of a protective benzodiazepine effect or a universal substitution recommendation. For a specific arrhythmia allegation, use the actual rhythm evidence, symptoms, treatment timeline, and competing causes rather than equating a claims marker with a confirmed diagnosis.
Source paper
Original analysis of the supplied journal article, identified as PMC6223696.